Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease

References

• Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol.6, 734–746 (2007).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch. Neurol.62, 1160–1163; discussion 1167 (2005).
   PubMed Web of Science ®Google Scholar
• Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC. Apolipoprotein E ε4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the cache county study. Arch. Gen. Psychiatry61, 518–524 (2004).
   PubMed Web of Science ®Google Scholar
• Herholz K. FDG-PET: Imaging cerebral glucose metabolism with positron emission tomography. In: The Dementias – Early Diagnosis and Evaluation. Herholz K, Perani D, Morris C (Eds). Taylor & Francis, NY, USA, 229–252 (2006).
   Google Scholar
• Langbaum JB, Chen K, Lee W et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer‘s Disease Neuroimaging Initiative (ADNI). NeuroImage45, 1107–1116 (2009).
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS. Applications of neuroimaging to disease-modification trials in Alzheimer’s disease. Behav. Neurol.21, 129–136 (2009).
   PubMed Web of Science ®Google Scholar
• Varrone A, Asenbaum S, Vander Borght T et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur. J. Nucl. Med. Mol. Imaging DOI: 10.1007/s00259-009-1264-0 (2009) (Epub ahead of print).
   Google Scholar
• Herholz K. PET studies in dementia. Ann. Nucl. Med.17, 79–89 (2003).
   PubMedGoogle Scholar
• Herholz K, Perani D, Salmon E et al. Comparability of FDG-PET studies in probable Alzheimer‘s disease. J. Nucl. Med.34, 1460–1466 (1993).
   PubMedGoogle Scholar
• Herholz K, Nordberg A, Salmon E et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.10, 494–504 (1999).
   PubMed Web of Science ®Google Scholar
• Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three- dimensional stereotactic surface projections of fluorine-18-FDG-PET. J. Nucl. Med.36, 1238–1248 (1995).
   PubMed Web of Science ®Google Scholar
• Signorini M, Paulesu E, Friston K et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG-PET: a clinical validation of statistical parametric mapping. Neuroimage9, 63–80 (1999).
   PubMed Web of Science ®Google Scholar
• Herholz K, Salmon E, Perani D et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG-PET. Neuroimage17, 302–316 (2002).
   PubMed Web of Science ®Google Scholar
• Kippenhan JS, Barker WW, Nagel J, Grady C, Duara R. Neural-network classification of normal and Alzheimer’s disease subjects using high-resolution and low-resolution PET cameras. J. Nucl. Med.35, 7–15 (1994).
   PubMed Web of Science ®Google Scholar
• Sayeed A, Petrou M, Spyrou N, Kadyrov A, Spinks T. Diagnostic features of Alzheimer’s disease extracted from PET sinograms. Phys. Med. Biol.47, 137–148 (2002).
   PubMed Web of Science ®Google Scholar
• Nobili F, Salmaso D, Morbelli S et al. Principal component analysis of FDG-PET in amnestic MCI. Eur. J. Nucl. Med. Mol. Imaging35, 2191–2202 (2008).
   PubMedGoogle Scholar
• Salmon E, Kerrouche N, Perani D et al. On the multivariate nature of brain metabolic impairment in Alzheimer’s disease. Neurobiol. Aging30, 186–197 (2009).
   PubMedGoogle Scholar
• Higdon R, Foster NL, Koeppe RA et al. A comparison of classification methods for differentiating frontotemporal dementia from Alzheimer’s disease using FDG-PET imaging. Stat. Med.23, 315–326 (2004).
   PubMedGoogle Scholar
• Wienhard K, Pawlik G, Herholz K, Wagner R, Heiss WD. Estimation of local cerebral glucose utilization by positron emission tomography of 18F]2-fluoro-2-deoxy-D-glucose: a critical appraisal of optimization procedures. J. Cereb. Blood Flow Metab.5, 115–125 (1985).
   PubMed Web of Science ®Google Scholar
• Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp.2, 189–210 (1995).
   Google Scholar
• Yakushev I, Hammers A, Fellgiebel A et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging. Neuroimage44, 43–50 (2009).
   PubMed Web of Science ®Google Scholar
• Heiss WD, Pawlik G, Holthoff V, Kessler J, Szelies B. PET correlates of normal and impaired memory functions. Cerebrovasc. Brain Metab. Rev.4, 1–27 (1992).
   PubMedGoogle Scholar
• Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann. Neurol.54, 343–351 (2003).
   PubMed Web of Science ®Google Scholar
• De Santi S, de Leon MJ, Rusinek H et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging22, 529–539 (2001).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Tsui WH, Herholz K et al. Multicenter standardized 18F-FDG-PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J. Nucl. Med.49, 390–398 (2008).
   PubMed Web of Science ®Google Scholar
• Aston JA, Cunningham VJ, Asselin MC, Hammers A, Evans AC, Gunn RN. Positron emission tomography partial volume correction: estimation and algorithms. J. Cereb. Blood Flow Metab.22, 1019–1034 (2002).
   PubMedGoogle Scholar
• Klein JC, Herholz K, Wienhard K, Heiss WD. Cortical flattening applied to high-resolution 18F-FDG-PET. J. Nucl. Med.49, 44–49 (2008).
   PubMedGoogle Scholar
• Mourik JE, Lubberink M, van Velden FH et al. In vivo validation of reconstruction-based resolution recovery for human brain studies. J. Cereb. Blood Flow Metab.30(2), 381–389 (2009).
   PubMedGoogle Scholar
• Pardo JV, Lee JT, Sheikh SA et al. Where the brain grows old: decline in anterior cingulate and medial prefrontal function with normal aging. Neuroimage35, 1231–1237 (2007).
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Ishii K, Sasaki M et al. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer’s disease. J. Neurol. Sci.200, 27–32 (2002).
   PubMed Web of Science ®Google Scholar
• Haense C, Herholz K, Jagust WJ, Heiss WD. Performance of FDG-PET for detection of alzheimer’s disease in two independent multicenter samples (NEST-DD and ADNI). Dement. Geriatr. Cogn. Disord.28, 259–266 (2009).
   PubMed Web of Science ®Google Scholar
• Silverman DH, Small GW, Chang CY et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA286, 2120–2127 (2001).
   PubMed Web of Science ®Google Scholar
• Foster NL, Heidebrink JL, Clark CM et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain130, 2616–2635 (2007).
   PubMed Web of Science ®Google Scholar
• Jagust W, Reed B, Mungas D, Ellis W, DeCarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology69, 871–877 (2007).
   PubMed Web of Science ®Google Scholar
• Small GW, Mazziotta JC, Collins MT et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA273, 942–947 (1995).
   PubMed Web of Science ®Google Scholar
• Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the ε 4 allele for apolipoprotein E. N. Eng. J. Med.334, 752–758 (1996).
   PubMed Web of Science ®Google Scholar
• Reiman EM, Chen K, Alexander GE et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl Acad. Sci. USA101, 284–289 (2004).
   PubMed Web of Science ®Google Scholar
• Small GW, Ercoli LM, Silverman DH et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc. Natl Acad. Sci. USA97, 6037–6042 (2000).
   PubMed Web of Science ®Google Scholar
• de Leon MJ, Convit A, Wolf OT et al. Prediction of cognitive decline in normal elderly subjects with 2-F-18-fluoro-2-deoxy-D-glucose positron-emission tomography (FDG-PET). Proc. Natl Acad. Sci. USA98, 10966–10971 (2001).
   PubMed Web of Science ®Google Scholar
• Hampel H, Frank R, Broich K et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov.9, 560–574 (2010).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Tsui WH, DeSanti S et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology641860–1867 (2005).
   PubMed Web of Science ®Google Scholar
• Clerici F, Del Sole A, Chiti A et al. Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. Q. J. Nucl. Med. Mol. Imaging53, 646–657 (2009).
   PubMed Web of Science ®Google Scholar
• Jauhiainen AM, Kangasmaa T, Rusanen M et al. Differential hypometabolism patterns according to mild cognitive impairment subtypes. Dement. Geriatr. Cogn. Disord.26, 490–498 (2008).
   PubMedGoogle Scholar
• Chetelat G, Desgranges B, Landeau B et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer’s disease. Brain131, 60–71 (2008).
   PubMedGoogle Scholar
• Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann. Neurol.42, 85–94 (1997).
   PubMed Web of Science ®Google Scholar
• Berent S, Giordani B, Foster N et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer’s disease. J. Psychiatr. Res.33, 7–16 (1999).
   PubMed Web of Science ®Google Scholar
• Arnaiz E, Jelic V, Almkvist O et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport12, 851–855 (2001).
   PubMed Web of Science ®Google Scholar
• Drzezga A, Grimmer T, Riemenschneider M et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG-PET. J. Nucl. Med.46, 1625–1632 (2005).
   PubMed Web of Science ®Google Scholar
• Anchisi D, Borroni B, Franceschi M et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol.62, 1728–1733 (2005).
   PubMedGoogle Scholar
• Fellgiebel A, Siessmeier T, Scheurich A et al. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol. Psychiatry56, 279–283 (2004).
   PubMed Web of Science ®Google Scholar
• Fellgiebel A, Scheurich A, Bartenstein P, Muller MJ. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res.155, 167–171 (2007).
   PubMedGoogle Scholar
• Landau SM, Harvey D, Madison CM et al.; on behalf of the Alzheimer’s Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology75, 230–238 (2010).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Tsui WH, Pupi A et al.18F-FDG-PET Database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer’s disease. J. Nucl. Med.48, 1129–1134 (2007).
   PubMedGoogle Scholar
• Drzezga A, Lautenschlager N, Siebner H et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging30, 1104–1113 (2003).
   PubMed Web of Science ®Google Scholar
• Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer’s disease. Neurology38, 909–912 (1988).
   PubMed Web of Science ®Google Scholar
• Haxby JV, Grady CL, Koss E et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol.47, 753–760 (1990).
   PubMedGoogle Scholar
• Brown DRP, Hunter R, Wyper DJ et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer’s disease: A SPECT blood flow study. J. Psychiatr. Res.30, 109–126 (1996).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Mistur R, Switalski R et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging36, 811–822 (2009).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Perani D, Sorbi S et al. Brain metabolism predicts conversion from mild cognitive impairment to dementia in individual carriers of the ApoE E4 allele. Eur. J. Neurol.11(Suppl. 2), 27 (2004).
   Google Scholar
• Haxby JV, Rapoport SI. Abnormalities of regional brain metabolism in Alzheimer’s disease and their relation to functional impairment. Prog. Neuropsychopharmacol. Biol. Psychiatry10, 427–438 (1986).
   PubMed Web of Science ®Google Scholar
• Desgranges B, Baron JC, Lalevee C et al. The neural substrates of episodic memory impairment in Alzheimer’s disease as revealed by FDG-PET: relationship to degree of deterioration. Brain125, 1116–1124 (2002).
   PubMedGoogle Scholar
• Cummings JL. Integrating ADNI results into Alzheimer’s disease drug development programs. Neurobiol. Aging31, 1481–1492 (2010).
   PubMed Web of Science ®Google Scholar
• Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am. J. Psychiatry159, 738–745 (2002).
   PubMed Web of Science ®Google Scholar
• Hirono N, Hashimoto M, Ishii K, Kazui H, Mori E. One-year change in cerebral glucose metabolism in patients with Alzheimer’s disease. J. Neuropsychiatry Clin. Neurosci.16, 488–492 (2004).
   PubMedGoogle Scholar
• Holland D, Brewer JB, Hagler DJ et al. Subregional neuroanatomical change as a biomarker for Alzheimer’s disease. Proc. Natl Acad. Sci. USA106, 20954–20959 (2009).
   PubMed Web of Science ®Google Scholar
• Landau SM, Harvey D, Madison CM et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2009.07.002 (2009).
   PubMedGoogle Scholar
• Chen K, Langbaum JB, Fleisher AS et al. Twelve-month metabolic declines in probable Alzheimer‘s disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer‘s Disease Neuroimaging Initiative. Neuroimage51, 654–664 (2010).
   PubMed Web of Science ®Google Scholar
• Garibotto V, Borroni B, Kalbe E et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology71, 1342–1349 (2008).
   PubMed Web of Science ®Google Scholar
• Edison P, Archer HA, Hinz R et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG-PET study. Neurology68, 501–508 (2007).
   PubMed Web of Science ®Google Scholar
• Li Y, Rinne JO, Mosconi L et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging35, 2169–2181 (2008).
   PubMed Web of Science ®Google Scholar
• Cohen AD, Price JC, Weissfeld LA et al. Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve. J. Neurosci.29, 14770–14778 (2009).
   PubMedGoogle Scholar
• Lowe VJ, Kemp BJ, Jack CR Jr et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med.50, 878–886 (2009).
   PubMed Web of Science ®Google Scholar
• Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology60, 1374–1377 (2003).
   PubMed Web of Science ®Google Scholar